Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PBYI
CUSIPN/A
Phone424-248-6500
Debt
Debt-to-Equity Ratio0.85
Current Ratio1.91
Quick Ratio1.87
Price-To-Earnings
Trailing P/E Ratio-6.74
Forward P/E Ratio-13.81
P/E GrowthN/A
Sales & Book Value
Annual Sales$26.20 million
Price / Sales76.34
Cash FlowN/A
Price / CashN/A
Book Value$1.42 per share
Price / Book37.25
Profitability
EPS (Most Recent Fiscal Year)($7.85)
Net Income$-291,950,000.00
Net MarginsN/A
Return on Equity-314.05%
Return on Assets-141.14%
Miscellaneous
Employees318
Outstanding Shares37,810,000
Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions
What is Puma Biotechnology's stock symbol?
Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."
How were Puma Biotechnology's earnings last quarter?
Puma Biotechnology Inc (NASDAQ:PBYI) issued its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping analysts' consensus estimates of ($1.26) by $0.61. The biopharmaceutical company earned $66.50 million during the quarter, compared to analysts' expectations of $67.33 million. During the same quarter in the previous year, the business earned ($1.16) EPS. View Puma Biotechnology's Earnings History.
When is Puma Biotechnology's next earnings date?
What price target have analysts set for PBYI?
9 brokers have issued 1 year price objectives for Puma Biotechnology's stock. Their forecasts range from $68.00 to $146.00. On average, they expect Puma Biotechnology's share price to reach $102.2222 in the next year. View Analyst Ratings for Puma Biotechnology.
Who are some of Puma Biotechnology's key competitors?
Some companies that are related to Puma Biotechnology include SAGE Therapeutics (SAGE), Alkermes (ALKS), Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Loxo Oncology (LOXO), FibroGen (FGEN), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Madrigal Pharmaceuticals (MDGL) and HUTCHISON CHINA/S (HCM).
Who are Puma Biotechnology's key executives?
Puma Biotechnology's management team includes the folowing people:
- Mr. Alan H. Auerbach, Founder, Chairman, CEO, Pres & Sec. (Age 48)
- Mr. Charles R. Eyler, Sr. VP of Fin. & Admin. and Treasurer (Age 70)
- Dr. Richard P. Bryce MBChB, MRCGP, MFPM, Chief Medical & Scientific Officer (Age 61)
- Mr. Steven Lo, Chief Commercial Officer (Age 51)
- Mr. Douglas Hunt, Sr. VP of Regulatory Affairs, Medical Writing & Project Management
Has Puma Biotechnology been receiving favorable news coverage?
Media coverage about PBYI stock has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Puma Biotechnology earned a media sentiment score of 0.16 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 45.40 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Puma Biotechnology's major shareholders?
Puma Biotechnology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.28%), Point72 Asset Management L.P. (3.39%), Redmile Group LLC (2.90%), Franklin Resources Inc. (2.27%), venBio Select Advisor LLC (2.18%) and Rock Springs Capital Management LP (1.09%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Charles R Eyler, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.
Which major investors are selling Puma Biotechnology stock?
PBYI stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, UBS Group AG, Millennium Management LLC, Eversept Partners LLC, BlackRock Inc., Sivik Global Healthcare LLC, California Public Employees Retirement System and Teacher Retirement System of Texas. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Charles R Eyler and Richard Paul Bryce. View Insider Buying and Selling for Puma Biotechnology.
Which major investors are buying Puma Biotechnology stock?
PBYI stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., venBio Select Advisor LLC, Summit Trail Advisors LLC, Redmile Group LLC, BNP Paribas Arbitrage SA, PointState Capital LP, Federated Investors Inc. PA and Rock Springs Capital Management LP. View Insider Buying and Selling for Puma Biotechnology.
How do I buy shares of Puma Biotechnology?
Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Puma Biotechnology's stock price today?
One share of PBYI stock can currently be purchased for approximately $52.90.
How big of a company is Puma Biotechnology?
Puma Biotechnology has a market capitalization of $1.98 billion and generates $26.20 million in revenue each year. The biopharmaceutical company earns $-291,950,000.00 in net income (profit) each year or ($7.85) on an earnings per share basis. Puma Biotechnology employs 318 workers across the globe.
How can I contact Puma Biotechnology?
Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]
MarketBeat Community Rating for Puma Biotechnology (PBYI)
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe PBYI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBYI will underperform the S&P 500 over the long term. You may vote once every thirty days.
